• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 21, 2023
Product Development

ADC advances at AACR: target diversity, optimizing internalization

BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
Read More
BioCentury | Sep 9, 2022
Product Development

China driving solid tumor CAR T innovation

Chinese investigator-initiated trials are accelerating CAR T innovation, bringing solid tumor advances to ESMO22
Read More
BioCentury | May 26, 2022
Product Development

Early promise for Enterome’s microbiome-derived cancer vaccine

ASCO data show 54.5% ORR for EO2401/Opdivo/Avastin combo in glioblastoma
Read More
BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

BioCentury’s roundup of preclinical news
Read More
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

The targets and indications CAR T developers are exploring to get to efficacy in solid tumors
Read More
BioCentury | Jun 22, 2018
Targets & Mechanisms

T cell balancing act

The latest debate in CAR T is whether CD8+ or CD4+ cells play the bigger role
Read More
BioCentury | Mar 29, 2018
Translation in Brief

Putting GBM in Check

How MCSP may be the next best thing for GBM CAR T therapy
Read More
BioCentury | Dec 22, 2017
Clinical News

Stemline reports additional Phase II data for SL-701 in GBM

Read More
BioCentury | Aug 22, 2017
Financial News

Mustang Bio lists on NASDAQ

Read More
BioCentury | Feb 2, 2017
Financial News

Mustang raises $94.5M in private placement

Read More
Items per page:
1 - 10 of 20